COMP <GO>
PTGX vs UNH // FREE CASH FLOW YIELD
Protagonist Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: PTGX 3
— UNH 11
▲ FREE CASH FLOW YIELD LEADER: UNH
LAST: $144.85 (+0.35%) • MKT CAP: $9.34B
fcf-yield
0.60%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
fcf-yield
6.48%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTGX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTGX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 88.57% | -47.57 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -16.70% | 11.47% | -28.17 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 16.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 0.60% | 6.48% | -5.88 | UNH | /fcf-yield <GO> |
| Operating Margin | -6.00% | 4.82% | -10.82 | UNH | /operating-margins <GO> |
| Net Profit Margin | -5.00% | 3.14% | -8.14 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 0.00% | 6.46% | -6.46 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 3.12 | +22.88 | PTGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.74% | +0.16 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.9 | 56.0 | +1.86 | PTGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.33 | +0.66 | PTGX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 17.1x | +13.91 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.34B | $364.66B | -$355.32B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTGX REV | UNH REV | PTGX GROSS % | UNH GROSS % | PTGX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $447.57B | — | 88.7% | $56.1M | $16.07B |
| FY 2024 | $0 | $400.28B | — | 88.3% | $182.8M | $20.70B |
| FY 2023 | $0 | $371.62B | — | 89.6% | -$70.2M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTGX // BETA 0.99
UNH // BETA 0.33